Business Context and Reporting Period
Company: Inspire Medical Systems, Inc. (INS)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2025
Business Overview: Inspire is a medical technology company focused on the development and commercialization of the Inspire system, a neurostimulation therapy for moderate to severe obstructive sleep apnea (OSA). The company operates as a single segment, selling primarily to hospitals and ambulatory surgery centers in the U.S., Europe, and the Asia Pacific region.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $201,317 | $164,010 |
| Gross Profit | $170,608 | $139,253 |
| Gross Margin | 84.7% | 84.9% |
| Operating Loss | $(1,485) | $(15,218) |
| Net Income (Loss) | $2,992 | $(10,005) |
| Diluted EPS | $0.10 | $(0.34) |
| Cash and Cash Equivalents | $53,882 | $175,416 |
| Total Investments (Short & Long Term) | $360,138 | $N/A |
| Working Capital | $508,209 | $N/A |
| Net Cash Used in Operating Activities | $(6,703) | $8,860 |
Note: The company reported a net income of $3.0 million in Q1 2025, a turnaround from a net loss of $10.0 million in the prior year period. Total cash, cash equivalents, and investments stood at $414.0 million as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22.7% year-over-year to $201.3 million. This was driven by a 24.3% increase in U.S. revenue ($193.6 million), offset by a 6.4% decline in international revenue ($7.7 million).
- Profitability: The company achieved net income of $3.0 million compared to a net loss of $10.0 million in Q1 2024. Operating loss narrowed significantly from $15.2 million to $1.5 million.
- Expense Trends:
- SG&A: Increased 14.9% to $144.3 million, primarily due to a $17.4 million increase in compensation and headcount.
- R&D: Decreased 3.6% to $27.8 million, driven by lower ongoing development costs for next-generation systems, partially offset by higher compensation.
- Liquidity: Cash and cash equivalents decreased by $96.3 million to $53.9 million, primarily due to $75.0 million in share repurchases and inventory build-up.
Guidance, Outlook, and Risks
- Product Transition (Inspire V): The company received FDA approval for the next-generation Inspire V system in August 2024, with a full U.S. launch expected in 2025. Management noted that some patients and physicians are delaying therapy until Inspire V is available, and customers are destocking existing Inspire IV inventory. This is expected to impact consolidated revenue, primarily in Q2 2025.
- Competitive Landscape: The company highlighted the impact of GLP-1 drugs (e.g., Zepbound) approved for OSA treatment. While management believes these drugs may reduce BMI and potentially expand the eligible patient pool for Inspire therapy in the long term, there is a risk of reduced demand if GLP-1s resolve OSA for some patients.
- Legal Proceedings:
- Securities Litigation: A federal securities class action (City of Hollywood Lawsuit) was dismissed with prejudice in March 2025. A related derivative lawsuit (Hollin Lawsuit) has a pending motion for voluntary dismissal.
- Government Investigation: In January 2025, the company received a Civil Investigative Demand (CID) from the DOJ regarding marketing and reimbursement practices under the False Claims Act. The company is cooperating, and the outcome is uncertain.
- Capital Allocation: The company completed its $150 million share repurchase program in Q1 2025. No amount remains available for future repurchases under the current authorization.
Investor Verification Checklist
- Revenue Sustainability: Verify the extent of revenue impact from the transition to Inspire V and customer destocking of Inspire IV inventory in Q2 2025.
- GLP-1 Impact: Monitor clinical data and market trends regarding the efficacy of GLP-1 drugs on OSA resolution versus Inspire therapy indications.
- DOJ Investigation: Track the status and potential outcomes of the False Claims Act investigation initiated in January 2025.
- International Recovery: Assess the recovery of European revenue following the resolution of EU MDR certification delays for silicone-based leads.
- Cash Burn vs. Income: Reconcile the reported net income with the negative operating cash flow ($6.7 million used), driven by working capital changes (inventory build-up) and share repurchases.